Back to News
Market Impact: 0.2
Patronus Biotech reçoit l'approbation éthique pour lancer en Australie un essai de phase 1, le premier chez l'humain, de trois vaccins multi-étapes contre le paludisme.
Source: PR Newswire
Healthcare & Biotech
Bellberry Limited’s research ethics committee approved the first-in-human study in Australia of Patronus Biotech’s multistage malaria vaccine candidates. The VLP-based candidates target Plasmodium falciparum and another Plasmodium species, but the available text provides no trial size, results, or efficacy data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Sovereign wealth funds' China and Hong Kong investments surge 190% after a bruising slump
- Arcus Biosciences prices $250 million stock offering at $17.50
- AstraZeneca says U.S. FDA approves rare kidney disease drug
- UnitedHealth's Earnings Jumped 60%. Is the Comeback Stock a Buy, Sell, or Hold?
- Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
- Why is Intuitive Surgical stock tumbling today?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience
- How to Build an Automated Research Process for a Fund